08:16 AM EDT, 07/15/2025 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) on Tuesday said it added the Mayo Clinic to its ongoing Phase 3 clinical study in metastatic breast cancer.
The company's late-stage study now has 69 active clinical sites across 15 states. BriaCell's Phase 3 clinical study is evaluating its lead clinical candidate, Bria-IMT, plus immune check point inhibitor versus physician's choice in advanced metastatic breast cancer (Bria-ABC).
Shares of the company closed down 0.7% at $2.77 on Monday on the Toronto Stock Exchange.